Inventaire - your friends and communities are your best library

Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management.

author

Vicente Arroyo

1945 -

Jordi Colmenero

published in: Journal of Hepatology

date of publication: 2003-01-01

main subject: liver cirrhosis, pathophysiology, hepatorenal syndrome

Cites articles 169

Date

Title

Authors

2002-05-01

Hepatorenal syndrome in cirrhosis: pathogenesis and treatment

Pere Ginès, Vicente Arroyo
2002-02-01

Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites

Vicente Arroyo
2002-08-01

Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study

Christophe Hézode, Françoise Roudot-Thoraval
2002-01-01

Preliminary results of a new expanded-polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt procedures
2002-12-01

Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis

Pere Ginès, Vicente Arroyo, Jaime Bosch, Joan Rodés Teixidor, Ramón Plana, Juan Uriz, Blas Calahorra, Patrick S Kamath
2002-04-01

Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study

Francois Durand, Dominique C Valla, Thierry Poynard, Didier Samuel
2002-10-01

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study

Pere Ginès, Andres Cardenas, Vicente Arroyo, Joan Rodés Teixidor, Juan Uriz, Blas Calahorra, Wladimiro Jiménez
2001-01-01

A prognostic model for predicting survival in cirrhosis with ascites

Pere Ginès, Andres Cardenas, Wladimiro Jiménez, Vicente Arroyo, Gloria Fernández-Esparrach
2001-08-01

Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis

Rafael Bañares, Juan Carlos García-Pagan
2001-02-01

Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis
2000-01-01

Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem
2000-07-01

Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome
2000-01-01

Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis

Dominique C Valla
2000-06-01

A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites

Maximilian Reiser
2000-08-01

Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study
1999-08-01

Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis

Victor Manuel Vargas Blasco, German Soriano
1999-05-01

Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt
1999-02-01

Signed consent for publication
1999-10-01

Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine

Alexander Gerbes
1999-06-01

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide
1998-07-01

Increased cerebrovascular resistance in cirrhotic patients with ascites.

Pere Ginès, Wladimiro Jiménez, Vicente Arroyo, Gloria Fernández-Esparrach
1998-05-01

Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality

Miquel Navasa, Wladimiro Jiménez, Vicente Arroyo
1998-01-01

Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion
1998-09-01

Hyponatremia in cirrhosis: from pathogenesis to treatment

Pere Ginès, Daniel-G. Bichet, Robert William Schrier
1998-07-01

5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors
1998-01-01

VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist
1998-01-01

Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist
1998-05-01

Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis
1998-12-01

Acute effects of transjugular intrahepatic portosystemic stent-shunt (TIPSS) procedure on renal blood flow and cardiopulmonary hemodynamics in cirrhosis

Adrian J. Stanley, Peter C. Hayes, Doris N Redhead
1998-08-01

Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems

Pere Ginès, Wladimiro Jiménez, Juan Carlos García-Pagan, Vicente Arroyo
1997-01-01

Pathogenesis of ascites in cirrhosis,Pathogenesis of Ascites in Cirrhosis

Pere Ginès
1997-01-01

Neural control of renal function

Article - wd:Q35068045

Welcome to Inventaire

the library of your friends and communities

learn more